Zacks Research Reduces Earnings Estimates for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Analysts at Zacks Research cut their Q3 2025 earnings estimates for shares of Zimmer Biomet in a research report issued on Monday, November 25th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $1.95 for the quarter, down from their prior estimate of $1.98. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s FY2025 earnings at $8.48 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.34 EPS, Q3 2026 earnings at $2.20 EPS and FY2026 earnings at $9.13 EPS.

A number of other research firms have also weighed in on ZBH. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. Robert W. Baird lowered their price objective on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Oppenheimer lowered their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 15th. Raymond James lowered their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Finally, TD Cowen lowered their price objective on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a research note on Friday, September 6th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $123.22.

Zimmer Biomet Trading Down 0.3 %

ZBH opened at $110.64 on Wednesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The company’s 50 day simple moving average is $106.95 and its two-hundred day simple moving average is $109.47. The firm has a market capitalization of $22.03 billion, a price-to-earnings ratio of 21.03, a price-to-earnings-growth ratio of 2.04 and a beta of 1.02. Zimmer Biomet has a 1-year low of $101.47 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.65 EPS.

Hedge Funds Weigh In On Zimmer Biomet

Several hedge funds have recently bought and sold shares of the company. Wilmington Savings Fund Society FSB lifted its stake in Zimmer Biomet by 7.7% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 6,196 shares of the medical equipment provider’s stock worth $669,000 after acquiring an additional 442 shares in the last quarter. Sanctuary Advisors LLC increased its holdings in Zimmer Biomet by 26.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,825 shares of the medical equipment provider’s stock worth $1,965,000 after purchasing an additional 3,776 shares during the period. Toronto Dominion Bank increased its holdings in Zimmer Biomet by 14.5% during the 3rd quarter. Toronto Dominion Bank now owns 68,747 shares of the medical equipment provider’s stock worth $7,421,000 after purchasing an additional 8,710 shares during the period. Neo Ivy Capital Management purchased a new stake in Zimmer Biomet during the 3rd quarter worth about $150,000. Finally, Brown Financial Advisors increased its holdings in Zimmer Biomet by 16.6% during the 3rd quarter. Brown Financial Advisors now owns 9,566 shares of the medical equipment provider’s stock worth $1,033,000 after purchasing an additional 1,361 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet’s payout ratio is 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.